JP2024542989A - 抗ｉｌ－１３ｒ抗体製剤 - Google Patents

抗ｉｌ－１３ｒ抗体製剤 Download PDF

Info

Publication number
JP2024542989A
JP2024542989A JP2024525152A JP2024525152A JP2024542989A JP 2024542989 A JP2024542989 A JP 2024542989A JP 2024525152 A JP2024525152 A JP 2024525152A JP 2024525152 A JP2024525152 A JP 2024525152A JP 2024542989 A JP2024542989 A JP 2024542989A
Authority
JP
Japan
Prior art keywords
formulation
antibody
seq
formulation according
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542989A5 (https=
Inventor
ルク，アラン
ムーア，ロバート
ケイ． チョウ，ダニー
ファン，ロビン
クラウス，ニルス
レイチェル，アンジェリカ
Original Assignee
アスラン ファーマシューティカルズ ピーティーイー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスラン ファーマシューティカルズ ピーティーイー リミテッド filed Critical アスラン ファーマシューティカルズ ピーティーイー リミテッド
Publication of JP2024542989A publication Critical patent/JP2024542989A/ja
Publication of JP2024542989A5 publication Critical patent/JP2024542989A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2024525152A 2021-10-29 2022-10-28 抗ｉｌ－１３ｒ抗体製剤 Pending JP2024542989A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SG10202112096R 2021-10-29
SG10202112096R 2021-10-29
US202263332737P 2022-04-20 2022-04-20
US63/332,737 2022-04-20
SG10202250847P 2022-08-29
SG10202250847P 2022-08-29
PCT/SG2022/050779 WO2023075700A1 (en) 2021-10-29 2022-10-28 Anti-il-13r antibody formulation

Publications (2)

Publication Number Publication Date
JP2024542989A true JP2024542989A (ja) 2024-11-19
JP2024542989A5 JP2024542989A5 (https=) 2025-10-31

Family

ID=84536171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525152A Pending JP2024542989A (ja) 2021-10-29 2022-10-28 抗ｉｌ－１３ｒ抗体製剤

Country Status (5)

Country Link
US (1) US20250325475A1 (https=)
EP (1) EP4422684A1 (https=)
JP (1) JP2024542989A (https=)
TW (1) TW202332466A (https=)
WO (1) WO2023075700A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012027828A2 (pt) * 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
CN113677708A (zh) * 2019-03-26 2021-11-19 亚狮康私人有限公司 采用抗il13r抗体或其结合片段的治疗

Also Published As

Publication number Publication date
EP4422684A1 (en) 2024-09-04
WO2023075700A1 (en) 2023-05-04
US20250325475A1 (en) 2025-10-23
TW202332466A (zh) 2023-08-16

Similar Documents

Publication Publication Date Title
JP7839234B2 (ja) 抗ｉｌ－３３中和モノクローナル抗体
US12428497B2 (en) Multispecific antibody constructs
US10323095B2 (en) Antibody-fynomer conjugates
US20200055959A1 (en) Single Linker FabFv Antibodies and Methods of Producing Same
JP6013487B2 (ja) Ｐｃｓｋ９に対する抗体およびその使用
JP6931750B2 (ja) 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
US20200277366A1 (en) MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F
JP2016505633A (ja) ＴＮＦα抗原結合性タンパク質
KR20210143788A (ko) 항-il-13r 항체 또는 이의 결합 단편을 이용하는 치료
JP2017533705A (ja) 抗ｔｎｆ−／抗ｉｌ−２３二重特異性抗体
US20240409647A1 (en) Bispecific binding proteins against alarmins and uses thereof
JP2024531353A (ja) 抗ｉｌ４ｒ抗体の医薬組成物及びその使用
JP2024542989A (ja) 抗ｉｌ－１３ｒ抗体製剤
JP7082053B2 (ja) ＴＮＦαに結合する抗体分子
WO2023075702A1 (en) Anti-il-13r antibody formulation
JP2024530978A (ja) 融合タンパク質を含む医薬組成物
CN118176019A (zh) 抗il-13r抗体配制品
JP2025529908A (ja) 高濃度抗ｉｌ１３ｒ抗体製剤
JP7280259B2 (ja) 非アルコール性脂肪性肝炎の抗ｈｕＴＮＦＲ１治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251023